- Home
- AMPL vs VRDN Comparison
AMPL vs VRDN Comparison
Compare AMPL & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPL
- VRDN
- Stock Information
- Founded
- AMPL 2012
- VRDN 2006
- Country
- AMPL United States
- VRDN United States
- Employees
- AMPL N/A
- VRDN N/A
- Industry
- AMPL EDP Services
- VRDN Medical Specialities
- Sector
- AMPL Technology
- VRDN Health Care
- Exchange
- AMPL Nasdaq
- VRDN Nasdaq
- Market Cap
- AMPL 1.5B
- VRDN 1.3B
- IPO Year
- AMPL 2021
- VRDN N/A
- Fundamental
- Price
- AMPL $12.72
- VRDN $15.07
- Analyst Decision
- AMPL Buy
- VRDN Strong Buy
- Analyst Count
- AMPL 10
- VRDN 11
- Target Price
- AMPL $13.40
- VRDN $38.50
- AVG Volume (30 Days)
- AMPL 1.3M
- VRDN 728.3K
- Earning Date
- AMPL 08-07-2025
- VRDN 08-07-2025
- Dividend Yield
- AMPL N/A
- VRDN N/A
- EPS Growth
- AMPL N/A
- VRDN N/A
- EPS
- AMPL N/A
- VRDN N/A
- Revenue
- AMPL $306,601,000.00
- VRDN $302,000.00
- Revenue This Year
- AMPL $12.82
- VRDN N/A
- Revenue Next Year
- AMPL $10.82
- VRDN $17,102.33
- P/E Ratio
- AMPL N/A
- VRDN N/A
- Revenue Growth
- AMPL 8.56
- VRDN 4.86
- 52 Week Low
- AMPL $7.37
- VRDN $9.90
- 52 Week High
- AMPL $14.88
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- AMPL 60.00
- VRDN 61.91
- Support Level
- AMPL $11.87
- VRDN $13.84
- Resistance Level
- AMPL $12.71
- VRDN $14.85
- Average True Range (ATR)
- AMPL 0.49
- VRDN 0.82
- MACD
- AMPL 0.00
- VRDN -0.03
- Stochastic Oscillator
- AMPL 90.91
- VRDN 82.81
About AMPL Amplitude Inc.
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue primarily through selling subscriptions to the platform. The company derives a majority of its revenue from the United States.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).